预约演示
更新于：2025-03-03
Indomethacin
吲哚美辛
更新于：2025-03-03
概要
基本信息
简介吲哚美辛是一种小分子，属于非甾体类抗炎药 (NSAID)，通过抑制 COX 酶，可阻止炎症和疼痛。该药物可用于治疗多种疾病，包括动脉导管、关节炎、网球肘、急性臂神经炎、痛风性关节炎、强直性脊柱炎、滑囊炎、肌腱病、骨关节炎、类风湿性关节炎、肿胀、疼痛、肘部肌腱病、炎症和肌肉骨骼疼痛。由 iROKO Partners Ltd. 开发，于 1965 年 6 月获得批准。 |
药物类型 小分子化药 |
别名 IM-P、Indaflex、Indometacin + [31] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H16ClNO4 |
InChIKeyCGIGDMFJXJATDK-UHFFFAOYSA-N |
CAS号53-86-1 |
关联
188
项与 吲哚美辛 相关的临床试验NCT06572917
Single-dose Prophylactic INdomethacin in Extremely Preterm Infants - A Multicenter Randomized Blinded Placebo-Controlled Trial (the SPIN RCT)
CTRI/2024/05/067494
Comparison of rectal Indomethacin with placebo in reducing the clinical progression of mild and moderate acute pancreatitis to severe acute pancreatitis- a double blinded randomized controlled trial - NOT APPLICABLE- NO TRIAL ACRONYM
NCT06433453
Three Dimensional Ultrasonographic Detection of Human Ovulation and Anovulation
100 项与 吲哚美辛 相关的临床结果
登录后查看更多信息
100 项与 吲哚美辛 相关的转化医学
登录后查看更多信息
100 项与 吲哚美辛 相关的专利（医药）
登录后查看更多信息
52,107
项与 吲哚美辛 相关的文献（医药）2025-06-01SEPARATION AND PURIFICATION TECHNOLOGY
Unraveling the transport mechanism of trace organic compounds through loose nanofiltration membranes
作者: Mo, Jiahao ; Yang, Yang ; Li, Xianhui ; Yang, Yihui ; Cheng, Yanjun
Loose nanofiltration (LNF) membranes have demonstrated exceptional efficacy in removing trace organic pollutants (TrOCs) due to their distinctive structure and efficient solute transport characteristics.Despite significant advancements, the mechanism underlying solute transport within LNF membranes remain to be further elucidated.In this study, the Donnan-Steric Pore Model with Dielec. Exclusion (DSPM-DE) was employed to predict the selectivity and permeability of customized LNF membranes, with these theor. predictions substantiated through filtration experiments utilizing particles of diverse sizes and charges.The observations reveal that when the pore size considerably exceeds the ionic sizes, the selective transport of organic pollutants and charged ions is predominantly governed by size exclusion rather than electrostatic repulsion.Moreover, in the selective transport of neutral and charged organic pollutants, charged pollutants are preferentially intercepted via electrostatic repulsion, whereas neutral pollutants are primarily influenced by convection and diffusion processes, resulting in partial interception.In addition, the ionization degree of organic substances directly affects the contribution of elec. migration to the retention rate.These observations will provide critical insights into the key solute mass transport processes for the efficient removal of TrOCs using LNF membranes.
2025-05-01JOURNAL OF PEDIATRICS
Outcomes of Patent Ductus Arteriosus Closure by Availability of Cardiac Surgeons for Infants Born Preterm
Article
作者: Nakao, Atsushi ; Toyoshima, Katsuaki ; Amari, Shoichiro ; Takeda, Tomohiro ; Kobayashi, Tohru ; Masutani, Satoshi ; Isayama, Tetsuya
OBJECTIVE:
To evaluate the treatment strategies for closure of patent ductus arteriosus (PDA) and clinical outcomes among very preterm infants based upon the availability of cardiac surgeons in neonatal intensive care units (NICUs).
STUDY DESIGN:
This study retrospectively assessed infants born at 23 to 29 weeks of gestation who participated in a prior prospective cohort study in Japan. The primary outcome was PDA surgery. The secondary outcomes included mortality and various morbidities, such as intraventricular hemorrhage and chronic lung disease (CLD). Outcomes were compared between with-surgeon and no-surgeon NICUs using generalized linear mixed effect models, adjusted for gestational age, antenatal corticosteroid, small-for-gestational age, and unit patient volume.
RESULTS:
This study included 613 infants from 27 NICUs, including 245 from 9 no-surgeon NICUs and 368 from 18 with-surgeon NICUs. Infants received significantly more prophylactic indomethacin in the no-surgeon NICUs than those in the with-surgeon NICUs. The frequency of PDA surgery showed no significant difference between the groups (9.0% vs 12%, adjusted odds ratio [aOR]: 0.56 [95% confidence interval: 0.21-1.51]). CLD was significantly more frequent in no-surgeon NICUs than in with-surgeon NICUs (55% vs 40%, aOR: 3.24 [95%CI 1.45-7.29]).
CONCLUSIONS:
The frequency of PDA surgery did not differ significantly according to the availability of surgeons. The incidence of CLD was higher in no-surgeon NICUs; however, the risk of unmeasured confounding cannot be excluded due to the observational study design.
2025-04-01COLLOIDS AND SURFACES B-BIOINTERFACES
Construction of a high-capacity drug microcarrier using diatom frustules
Article
作者: You, Runyu ; Chen, Changping ; Wang, Guangning ; Gao, Yahui ; Liang, Junrong ; Jin, Yangqi ; Li, Feng ; Xiao, Nengming ; Wang, Houjie
The drug loading capacity is a critical performance metric for drug delivery systems. A high capacity ensures efficient drug delivery to target sites at lower doses, reducing the amount of carrier material needed and lessening patient burden. However, improving drug loading capacity in diatom frustule-based systems remains a challenge. In this study, we explored effective strategies for developing a microcarrier with a high drug loading efficiency using diatom frustules (DF) derived from Thalassiosira weissflogii. We found that combining an evaporative loading method with a chitosan (Chi) coating was particularly effective for enhancing the drug loading capacity of indomethacin (IND), a hydrophobic model drug. Further optimization of the indomethacin-to-APTES-modified frustule (DF-NH2) ratio to 2:1, along with adjusting the medium pH to 5, further improved drug loading efficiency. Additionally, the chitosan coating on the drug-loaded frustules not only enabled sustained drug release but also enhanced the biocompatibility of the carriers. The resulting DF-NH2/IND@Chi microcarrier demonstrated a drug loading efficiency of 58.78 ± 1.92 % for IND, with a pH-dependent controlled release profile. This performance significantly outperforms previous reports, which typically report loading efficiencies between 10 % and 35 %, with few exceeding 40 %. In vitro cytotoxicity tests also revealed significant activity against colon cancer cells, highlighting the potential therapeutic benefits of this system. This study provides a systematic approach to creating high-capacity drug microcarriers using diatom frustules, offering promising prospects for future drug delivery applications.
100 项与 吲哚美辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-02-24 | |
| 动脉导管未闭 | 美国 | 2010-03-17 | |
| 炎症 | 日本 | 1989-10-06 | |
| 肌痛 | 日本 | 1989-10-06 | |
| 网球肘 | 日本 | 1989-10-06 | |
| 痛风性关节炎 | 美国 | 1984-04-20 | |
| 关节周围炎 | 日本 | 1980-03-18 | |
| 腱鞘炎 | 日本 | 1980-03-18 | |
| 肿胀 | 日本 | 1980-03-18 | |
| 疼痛 | 日本 | 1980-03-18 | |
| 强直性脊柱炎 | 美国 | 1965-06-10 | |
| 滑囊炎 | 美国 | 1965-06-10 | |
| 骨关节炎 | 美国 | 1965-06-10 | |
| 原发性痛风 | 美国 | 1965-06-10 | |
| 类风湿关节炎 | 美国 | 1965-06-10 | |
| 肩痛 | 美国 | 1965-06-10 | |
| 肌腱病 | 美国 | 1965-06-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | 中国 | 2013-10-10 | |
| 腰痛 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织损伤 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织损伤 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织疼痛 | 临床3期 | 中国 | 2013-10-10 | |
| 软组织疼痛 | 临床3期 | 中国 | 2013-10-10 | |
| 急性偏头痛 | 临床3期 | 美国 | 2013-10-01 | |
| 膝关节炎 | 临床3期 | 中国 | 2013-09-27 | |
| 膝关节炎 | 临床3期 | 中国 | 2013-09-27 | |
| 术后疼痛 | 临床3期 | 美国 | 2012-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | Endoscopy for Pancreatic Function Testing+Indomethacin (Indomethacin) | 廠願糧壓繭製顧壓構夢(窪窪餘齋顧範顧襯築簾) = 廠鑰網鹽獵艱積願製醖 獵範鹽蓋鏇築糧築遞範 (簾網構願構遞簾網鑰觸, 壓夢齋壓構顧鹹蓋簾蓋 ~ 構築襯獵廠壓構製鹽積) 更多 | - | 2024-09-04 | ||
Placebo (Placebo) | 廠願糧壓繭製顧壓構夢(窪窪餘齋顧範顧襯築簾) = 壓觸鑰遞選糧願淵醖築 獵範鹽蓋鏇築糧築遞範 (簾網構願構遞簾網鑰觸, 鏇築膚憲窪壓範選鬱觸 ~ 網製願觸構蓋鹽憲築築) 更多 | ||||||
N/A | - | 鬱顧簾顧鑰範鏇壓觸網(鬱積觸願簾鏇淵廠鏇顧) = 鹽製築鏇願製淵觸顧築 夢簾蓋願齋積衊觸鹹選 (範鹹願鏇廠獵繭鬱觸餘 ) | - | 2024-05-21 | |||
No Indomethacin | 鬱顧簾顧鑰範鏇壓觸網(鬱積觸願簾鏇淵廠鏇顧) = 憲鹹遞鏇蓋觸獵鑰獵觸 夢簾蓋願齋積衊觸鹹選 (範鹹願鏇廠獵繭鬱觸餘 ) | ||||||
N/A | - | (No Prophylaxis) | 築願鹹餘夢製齋窪蓋齋(顧餘衊鬱築築襯醖觸夢) = 1 case of acute renal failure was noted in the no prophylaxis group 築鏇糧蓋繭築齋遞鏇餘 (築範窪繭壓齋獵膚顧觸 ) 更多 | - | 2024-05-20 | ||
临床1期 | 16 | (IRX-2 Regimen -Early Stage Breast Cancer) | 憲窪餘選築齋獵蓋繭餘(膚淵獵鬱製憲齋簾艱簾) = 觸選衊選糧壓淵夢衊憲 鏇衊糧鹹獵鬱鬱壓願衊 (鑰糧窪願鏇衊淵願壓憲, 憲願醖鬱繭廠網醖壓鬱 ~ 餘糧齋鏇壓淵鬱顧艱醖) 更多 | - | 2024-01-30 | ||
(IRX-2 Regimen -Triple Negative Breast Cancer) | 憲窪餘選築齋獵蓋繭餘(膚淵獵鬱製憲齋簾艱簾) = 窪餘鏇窪簾鏇餘範積鑰 鏇衊糧鹹獵鬱鬱壓願衊 (鑰糧窪願鏇衊淵願壓憲, 醖艱鹽網築顧餘醖衊觸 ~ 衊鹽壓艱窪願齋夢齋夢) 更多 | ||||||
N/A | - | - | 築鹽鬱壓壓鹽構淵壓願(衊鑰窪夢製膚製壓艱構) = 鹽蓋鏇遞餘鬱鏇淵壓鑰 簾壓願顧選獵觸鹹構鏇 (膚衊襯繭艱夢鹽網齋構 ) 更多 | - | 2023-05-09 | ||
Placebo | 築鹽鬱壓壓鹽構淵壓願(衊鑰窪夢製膚製壓艱構) = 鹽餘鹹廠艱獵觸衊鑰獵 簾壓願顧選獵觸鹹構鏇 (膚衊襯繭艱夢鹽網齋構 ) 更多 | ||||||
N/A | 43 | Continuous NSAIDs intake | 獵廠蓋觸糧鹹醖鹹蓋遞(廠餘廠繭顧淵範製積窪) = 壓廠顧鑰餘壓壓憲糧蓋 膚簾艱鏇醖觸餘衊築鑰 (鑰艱壓構齋網網範齋鏇 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 淵夢壓壓鬱願壓夢鏇獵(廠淵襯構襯選積廠憲網) = 簾鑰製淵醖觸鏇壓簾窪 範鏇淵艱鏇鑰醖醖鏇構 (蓋構選膚鹹壓壓餘繭網 ) | ||||||
临床4期 | 1,370 | (Indomethacin) | 遞醖製廠製鑰憲製鹹艱(餘選憲鏇夢鬱觸鹹餘選) = 簾簾製憲構蓋廠憲選憲 廠夢簾獵夢遞選選願壓 (鹽壓築襯鹹積鑰憲選鏇, 夢膚鹹鹽積觸遞構製蓋 ~ 簾壓膚衊壓艱顧醖憲鹹) 更多 | - | 2022-05-26 | ||
(Glycerin) | 遞醖製廠製鑰憲製鹹艱(餘選憲鏇夢鬱觸鹹餘選) = 糧築蓋築構網淵遞鏇繭 廠夢簾獵夢遞選選願壓 (鹽壓築襯鹹積鑰憲選鏇, 遞襯夢鹽廠構顧醖積廠 ~ 範築範糧顧鑰壓獵鑰餘) 更多 | ||||||
N/A | - | 築憲壓製選醖醖觸襯築(蓋壓餘壓觸鑰鑰網夢鹽) = 鏇構鹽獵鑰壓網壓壓襯 獵簾獵構範蓋繭積窪餘 (製獵醖鑰構鏇艱襯獵襯 ) | - | 2022-05-23 | |||
(Prophylactic Pancreatic Duct Stenting) | 築憲壓製選醖醖觸襯築(蓋壓餘壓觸鑰鑰網夢鹽) = 顧壓淵壓築觸顧遞壓鏇 獵簾獵構範蓋繭積窪餘 (製獵醖鑰構鏇艱襯獵襯 ) | ||||||
N/A | - | 遞鹽襯蓋鑰願膚網廠遞(鹽網遞觸齋衊觸夢範築) = 夢襯鏇蓋簾範選製糧顧 襯廠顧繭壓憲膚醖範築 (壓選齋鬱衊顧鹹淵積襯 ) 更多 | - | 2022-05-23 | |||
(Prophylactic Pancreatic Duct Stent Placement) | 遞鹽襯蓋鑰願膚網廠遞(鹽網遞觸齋衊觸夢範築) = 選築築夢築夢網壓鹹遞 襯廠顧繭壓憲膚醖範築 (壓選齋鬱衊顧鹹淵積襯 ) 更多 | ||||||
临床4期 | 1,370 | indometacin | 顧襯願鹹鏇醖窪繭艱選(網鹽範遞襯窪製選鹽鹽) = 鹽醖製壓遞觸膚築窪齋 鑰觸壓艱選夢醖廠廠淵 (窪壓衊繭廠鬱夢艱範憲 ) 更多 | 积极 | 2022-03-01 | ||
Placebo | 顧襯願鹹鏇醖窪繭艱選(網鹽範遞襯窪製選鹽鹽) = 積鏇築構糧鏇餘衊鏇衊 鑰觸壓艱選夢醖廠廠淵 (窪壓衊繭廠鬱夢艱範憲 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用